- ISIN
- US51654W1018
- CUSIP
- 51654W101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 11, 2020
Highlights
- Market Cap
- $43.10M
- Enterprise Value
- $38.30M
- EPS (TTM)
- -$1.45
- EBITDA (TTM)
- -$16.42M
- Year Range
- $1.11 - $5.74
- ROA (TTM)
- -220.29%
- ROE (TTM)
- -461.79%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LTRN Performance Chart
Lantern Pharma Inc. (LTRN) is up 26.4% since the beginning of the year. At $4 per share, LTRN is trading 33.3% below its 52-week high of $6. Investors who bought $1,000 worth of LTRN shares 5 years ago would now be looking at an investment worth $258.
Loading charts...
Returns By Period
Lantern Pharma Inc. (LTRN) has returned 26.40% so far this year and 24.76% over the past 12 months.
Lantern Pharma Inc.
- 1D
- -1.29%
- 1M
- 9.43%
- YTD
- 26.40%
- 6M
- 9.43%
- 1Y
- 24.76%
- 3Y*
- -9.22%
- 5Y*
- -23.76%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
LTRN Monthly Returns History
Based on dividend-adjusted daily data since Jun 11, 2020, LTRN's average daily return is +0.05%, while the average monthly return is +0.56%. At this rate, an investment would double in approximately 10.3 years.
Historically, 40% of months were positive and 60% were negative. The best month was Mar 2024 with a return of +83.0%, while the worst month was Mar 2026 at -51.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, LTRN closed higher 45% of trading days. The best single day was Nov 9, 2023 with a return of +33.2%, while the worst single day was Mar 27, 2026 at -46.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.96% | -10.48% | -51.42% | 49.64% | 75.12% | 6.69% | 26.40% | ||||||
| 2025 | 55.17% | -20.20% | -10.38% | -0.56% | -13.35% | 3.61% | 40.51% | -8.11% | 6.62% | -7.82% | -9.73% | -16.30% | -5.02% |
| 2024 | -1.40% | 13.98% | 82.95% | -42.05% | 19.02% | -23.06% | -10.06% | -2.62% | -10.27% | -14.85% | 2.72% | -0.62% | -25.47% |
| 2023 | -0.33% | -8.81% | -12.02% | 1.45% | 6.33% | 8.25% | -17.91% | -2.38% | -24.56% | -27.27% | 59.27% | 8.35% | -29.14% |
| 2022 | -16.67% | -7.37% | 16.07% | -16.64% | -2.85% | -1.38% | -10.16% | 0.78% | -7.54% | -12.34% | 19.33% | 20.80% | -24.31% |
| 2021 | -21.92% | 18.23% | 2.08% | -17.25% | 0.73% | -3.44% | -11.64% | 9.22% | -20.65% | -8.68% | -17.34% | -5.45% | -58.55% |
Benchmark Metrics
Lantern Pharma Inc. has an annualized alpha of -5.14%, beta of 1.24, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since June 11, 2020.
- This stock participated in 231.21% of S&P 500 Index downside but only 159.49% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -5.14%
- Beta
- 1.24
- R²
- 0.06
- Upside Capture
- 159.49%
- Downside Capture
- 231.21%
Return for Risk
Risk / Return Rank
LTRN ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Lantern Pharma Inc. (LTRN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LTRN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.53 | ||
| Sortino ratioReturn per unit of downside risk | -1.35 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.32 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | 0.32 | 2.46 | -2.14 |
| Martin ratioReturn relative to average drawdown | 0.66 | 10.92 | -10.26 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lantern Pharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lantern Pharma Inc. was 94.89%, occurring on Mar 27, 2026. The portfolio has not yet recovered.
The current Lantern Pharma Inc. drawdown is 82.53%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -94.89%Mar 2026 | 5y 10d | — | 5y 3moMar 2021 - now |
2021 bear market2021 | -32.52%Jan 2021 | 3mo 18d | 2mo | 5mo 18dSep 2020 - Mar 2021 |
2020 bear market2020 | -28.43%Aug 2020 | 2mo 2d | 8d | 2mo 10dJun 2020 - Aug 2020 |
2020 correction2020 | -18.86%Sep 2020 | 9d | 7d | 16dAug 2020 - Sep 2020 |
2020 correction2020 | -16.79%Sep 2020 | 7d | 7d | 14dSep 2020 - Sep 2020 |
Drawdown Indicators
| LTRN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.89% | -56.78% | -38.11% |
Max Drawdown (1Y)Largest decline over 1 year | -78.95% | -9.10% | -69.85% |
Max Drawdown (3Y)Largest decline over 3 years | -89.48% | -18.90% | -70.58% |
Max Drawdown (5Y)Largest decline over 5 years | -92.66% | -25.43% | -67.23% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -82.53% | -3.21% | -79.32% |
Average DrawdownAverage peak-to-trough decline | -66.30% | -10.71% | -55.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.61% | 2.04% | +35.57% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lantern Pharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lantern Pharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LTRN in comparison with other companies in the Biotechnology industry. Currently, LTRN has a P/B value of 12.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LTRN
Add Lantern Pharma Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LTRN